Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.

26 juillet 2018 mis à jour par: GlaxoSmithKline

Study to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC With Priorix™, Versus MenC-CRM197 Vaccine With Hiberix™ & Priorix™ in Toddlers Primed With Hib But Not MenC & to Evaluate Persistence up to 5 Years After Vaccination.

The purpose of the primary phase of the study is to demonstrate the non-inferiority of a single dose of GSK Biologicals' Haemophilus influenzae type b and meningococcal C (Hib-MenC) conjugate vaccine when given in the second year of life to subjects primed in infancy with a Hib vaccine, but not with a meningococcal serogroup C vaccine, versus commercially available Hib and MenC vaccines.

In the extension phase, at Years 1, 2, 3, 4 & 5, one blood sample is taken at each year to follow the antibody persistence up to 5 years after vaccination. No additional vaccine is administered during the extension phase. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Aperçu de l'étude

Description détaillée

This multicenter study is open and has 2 treatment groups with Hiberix™ + a commercially available MenC vaccine as active controls. Priorix™ is given concomitantly in both groups. In the primary phase, two blood samples are taken from all subjects for immunogenicity analyses: before and one month after vaccination. In the extension phase, at Year 1, 2, 3, 4 & 5, one blood sample is taken at each year to follow the antibody persistence up to 5 years after vaccination. No additional vaccine is administered during the extension phase.

Type d'étude

Interventionnel

Inscription (Réel)

433

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Australian Capital Territory
      • Garran, Australian Capital Territory, Australie, 2606
        • GSK Investigational Site
    • New South Wales
      • Randwick, New South Wales, Australie, 2031
        • GSK Investigational Site
      • Westmead, New South Wales, Australie, 2145
        • GSK Investigational Site
    • Queensland
      • Herston, Queensland, Australie, 4029
        • GSK Investigational Site
    • South Australia
      • North Adelaide, South Australia, Australie, 5006
        • GSK Investigational Site
    • Victoria
      • Carlton, Victoria, Australie, 3053
        • GSK Investigational Site
    • Western Australia
      • Perth, Western Australia, Australie
        • GSK Investigational Site

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

1 an à 1 an (Enfant)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

Primary phase:

  • Subjects whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.
  • A male or female between, and including, 12 and 18 months of age at the time of vaccination.
  • Written informed consent obtained from the parent or guardian of the subject.
  • Free of obvious health problems as established by medical history and clinical examination before entering into the study.
  • Previously completed routine childhood vaccinations to the best of his/her parents'/guardians knowledge.
  • Having completed primary vaccination with two doses of Haemophilus influenzae type b outer membrane protein (Hib-OMP) containing vaccine OR three doses of diphtheria, tetanus, acellular pertussis and Haemophilus influenzae type b (DTPa/Hib) containing vaccine at least 6 months before the study start.

Long-term persistence phase:

- Having participated in the vaccination study 106445

Exclusion Criteria:

For the primary vaccination phase:

  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Chronic administration (defined as more than 14 days) or planned administration of immuno-suppressants or other immune-modifying drugs within six months prior to vaccination.
  • Planned administration/administration of a vaccine not foreseen by the protocol during the period starting from 30 days before vaccination and ending 30 days after vaccination.
  • Administration of a meningococcal vaccine not foreseen by the study protocol during the period starting at birth and ending at first dose.
  • Previous administration of a booster dose of Hib vaccine.
  • Previous vaccination against measles, mumps, rubella.
  • History of H. influenzae type b, meningococcal serogroup C and/or confirmed measles, mumps or rubella diseases.
  • Known exposure to measles, mumps or rubella within 30 days prior to the start of the study.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus infection.
  • A family history of congenital or hereditary immunodeficiency.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
  • Major congenital defects or serious chronic illness.
  • History of neurological disorders or more than one episode of febrile convulsion.
  • Acute disease at the time of enrolment.
  • Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.

Additional exclusion criteria for the long-term persistence phase: to be checked each year.

  • Previous administration of a booster dose of Hib, meningococcal serogroup C vaccines.
  • History of H. influenzae type b, meningococcal serogroup C diseases.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Meningitec + Hiberix Group
Subjects received a single dose of Meningitec™ vaccine co-administered with Hiberix™ and Priorix™ vaccines. The Meningitec vaccine was administered intramuscularly in the left deltoid region, the Hiberix vaccine was administered intramuscularly in the left thigh region and the Priorix vaccine was administered subcutaneously in the right upper arm.
One subcutaneous dose at 12-18 months of age
One intramuscular dose at 12-18 months of age.
One intramuscular dose at 12-18 months of age
Expérimental: Menitorix Group
Subjects received a single dose of Menitorix™ vaccine co-administered with Priorix™ vaccine. Menitorix vaccine was administered intramuscularly in the left deltoid region and the Priorix vaccine was administered subcutaneously in the right upper arm.
One subcutaneous dose at 12-18 months of age
One intramuscular dose at 12-18 months of age
Autres noms:
  • Hib-MenC
  • Menitorix™

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Micrograms Per Milliliter (µg/mL)
Délai: 1 month after vaccination
Anti-PRP antibody concentration greater than or equal to 0.15 µg/mL is indicative of short-term protection.
1 month after vaccination
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Greater Than or Equal to 1:8 Titer
Délai: 1 month after vaccination
rSBA-MenC titers greater than or equal to 1:8 titer are indicative of seroprotection.
1 month after vaccination

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Above the Cut-off Values
Délai: Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination

rSBA-MenC titers cut-off values assessed were greater than or equal to (≥) 1:8 (indicative of seroprotection) and ≥ 1:128 titers.

Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at a GlaxoSmithKline (GSK) laboratory up to Year 3 after vaccination, titres were expressed as the reciprocal of the dilution resulting in 50% inhibition. For SBA testing at the Public Health England (PHE), formerly known as Health Protection Agency (HPA), at Year 4, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.

Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Above the Cut-off Values
Délai: 5 years after vaccination
rSBA-MenC titers cut-off values assessed were greater than or equal to (≥)1:8 (indicative of seroprotection) and 1:128 titers. For SBA testing at the PHE at Year 5, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.
5 years after vaccination
Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers
Délai: Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination.
Titers are given as Geometric Mean Titers (GMTs). Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at a GlaxoSmithKline (GSK) laboratory up to Year 3 after vaccination, titres were expressed as the reciprocal of the dilution resulting in 50% inhibition. For SBA testing at the PHE at year 4 after vaccination, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.
Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination.
Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers
Délai: 5 years after vaccination
Titers are given as Geometric Mean Titers (GMTs). Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at the PHE at Year 5, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.
5 years after vaccination
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Above Cut-off Values
Délai: Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination
Anti-PRP antibody concentration cut-off values assessed include 0.15 µg/mL (indicative of short-term protection) and 1.0 µg/mL (indicative of long-term protection).
Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Above Cut-off Values
Délai: 5 years after vaccination
Anti-PRP antibody concentration cut-off values assessed include 0.15 µg/mL (indicative of short-term protection) and 1.0 µg/mL (indicative of long-term protection).
5 years after vaccination
Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations
Délai: Prior to, 1 month , 1 year, 2 years, 3 years and 4 years after vaccination
Concentrations are given as Geometric Mean Concentrations (GMCs).
Prior to, 1 month , 1 year, 2 years, 3 years and 4 years after vaccination
Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations
Délai: 5 years after vaccination
Concentrations are given as Geometric Mean Concentrations (GMCs).
5 years after vaccination
Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Above the Cut-off Values
Délai: Prior to, 1 month, 1 year, 2 years and 3 years after vaccination
Anti-PSC antibody concentration cut-off values assessed include greater than or equal to (≥) 0.30 µg/mL and ≥ 2.0 µg/mL.
Prior to, 1 month, 1 year, 2 years and 3 years after vaccination
Anti-polysaccharide C (Anti-PSC) Antibody Concentrations
Délai: Prior to, 1 month, 1 year, 2 years and 3 years after vaccination
Concentrations given as Geometric Mean Concentrations (GMCs).
Prior to, 1 month, 1 year, 2 years and 3 years after vaccination
Number of Subjects Reporting Solicited Local and General Symptoms
Délai: Within 4 days (Day 0 -Day 3) after vaccination

Solicited local symptoms assessed include pain, redness and swelling at the injection site.

Solicited general symptoms assessed include drowsiness, fever (≥ 38°C), irritability and loss of appetite.

Within 4 days (Day 0 -Day 3) after vaccination
Number of Subjects Reporting Unsolicited Symptoms
Délai: Within 31 days (Day 0 - Day 30) after vaccination
Unsolicited symptom: Any adverse event (AE) reported in addition to those solicited during the clinical study. Also any solicited symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.
Within 31 days (Day 0 - Day 30) after vaccination
Number of Subjects Reporting Serious Adverse Events (SAEs)
Délai: Throughout the entire study period (up to year 5)

A serious adverse event (SAE) is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study subject.

For the long-term persistence phase (Years 1 through 5), only those SAEs that are determined by the investigator to have a causal relationship to the vaccination will be described individually.

Throughout the entire study period (up to year 5)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 juin 2006

Achèvement primaire (Réel)

1 novembre 2007

Achèvement de l'étude (Réel)

6 novembre 2007

Dates d'inscription aux études

Première soumission

12 mai 2006

Première soumission répondant aux critères de contrôle qualité

12 mai 2006

Première publication (Estimation)

16 mai 2006

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

24 août 2018

Dernière mise à jour soumise répondant aux critères de contrôle qualité

26 juillet 2018

Dernière vérification

1 septembre 2016

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 106445
  • 106446 (Autre identifiant: GSK)
  • 106449 (Autre identifiant: GSK)
  • 106450 (Autre identifiant: GSK)
  • 106452 (Autre identifiant: GSK)
  • 106454 (Autre identifiant: GSK)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Données/documents d'étude

  1. Plan d'analyse statistique
    Identifiant des informations: 106445
    Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
  2. Formulaire de consentement éclairé
    Identifiant des informations: 106445
    Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
  3. Protocole d'étude
    Identifiant des informations: 106445
    Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
  4. Spécification du jeu de données
    Identifiant des informations: 106445
    Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
  5. Ensemble de données de participant individuel
    Identifiant des informations: 106445
    Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
  6. Rapport d'étude clinique
    Identifiant des informations: 106445
    Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner